Hemophilia

Latest News

Roctavian Gene Therapy Controls Bleeding for Five Years in Severe Hemophilia A
Roctavian Gene Therapy Controls Bleeding for Five Years in Severe Hemophilia A

July 23rd 2025

BioMarin's Roctavian gene therapy shows long-term effectiveness in treating severe hemophilia A, reducing bleeding and improving quality of life for patients.

Switching to Extended Half-Life Therapies Improves Hemophilia Care, but Raises Short-Term Costs
Switching to Extended Half-Life Therapies Improves Hemophilia Care, but Raises Short-Term Costs

July 18th 2025

Pfizer’s Hympavzi Cuts Bleeding by 93% in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Finds
Pfizer’s Hympavzi Cuts Bleeding by 93% in Hemophilia A and B Patients with Inhibitors, Phase 3 Trial Finds

July 8th 2025

Switching from Emicizumab to Mim8 Without a Washout Period Is Safe and Well-Tolerated in Hemophilia A Patients
Switching from Emicizumab to Mim8 Without a Washout Period Is Safe and Well-Tolerated in Hemophilia A Patients

July 1st 2025

Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade
Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade

June 17th 2025

Video Interviews
Podcasts
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.